Valuation
- Market cap
- 2,207,965,000
- Revenue TTM
- $6,940,000
- Net income TTM
- $-212,390,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- -3,060.37%
- Debt to equity
- 0.00
Trading
- Volume
- 951,000
- Avg volume
- 1,443,940
- Day's range
- $18.10 – $18.92
- Shares out
- 118,073,000
- Stochastic %K
- 27%
- Beta
- 2.68
- Analysts
- Strong Buy
- Price target
- $35.07
Company profile
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan r...
Show more
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 425 939 7410
- Website
- https://immunome.com
- Address
- 18702 North Creek Parkway, Suite 100, Bothell, United States
Latest news
No headlines yet.
